alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 451–475 of 1,139 studies in Cognitive tests and assessment marked Peer-reviewed (page 19 of 46) · 30,980 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,452 studies have no institution on record and are not counted here.

What “Cognitive tests and assessment” covers

Cognitive tests and assessment — Memory and thinking tests, screening tools and rating scales: how well they measure what they claim to.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Unveiling the potential of the Digits-in-Noise test as a hearing screening tool for older adults with cognitive impairment

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of Alzheimer's disease : JAD 2025-09-12

BackgroundThe Digits-in-Noise (DIN) test is recognized as a promising hearing screening tool due to its feasibility and reliability, particularly in noisy environments. 2 key findings →

Participants: 93 Evidence: low

Full summary, score breakdown and related studies → Original source

Driving into diagnosis: Leveraging high-resolution telematics and sensorimotor profiling to identify preclinical Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of Alzheimer's disease reports 2025-01-01

A high-frequency trip's driving telemetry, combined with age and APOE ε4 status, discriminates preclinical AD, outperforming multisensory measures. 1 key finding →

Participants: 254 Evidence: low

Full summary, score breakdown and related studies → Original source

Predicting brain amyloid load with digital and blood-based biomarkers

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Alzheimer's research & therapy 2025-07-05

The combination of MemTrax and BBMs provides an accurate, convenient, non-invasive, cost-effective and scalable way to estimate Aβ load, which provides an opportunity for mass screening and timely and accurate diagnosis of AD. 3 key findings →

Participants: 349 Evidence: low

Full summary, score breakdown and related studies → Original source

Artificial intelligence-driven natural language processing for identifying linguistic patterns in Alzheimer's disease and mild cognitive impairment: A study of lexical, syntactic, and cohesive features of speech through picture description tasks

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of Alzheimer's disease : JAD 2025-05-07

BackgroundLanguage deficits often occur early in the neurodegenerative process, yet traditional methods frequently fail to detect subtle changes. 3 key findings →

Design: post-hoc analysis Participants: 336 Evidence: low

Full summary, score breakdown and related studies → Original source

Digital screening tool for the assessment of cognitive impairment in unsupervised setting-digiDEM-SCREEN: study protocol for a validation study

✓ Peer-reviewed alzhub usefulness score 53 out of 100. BMJ open 2025-01-11

Dementia is one of the most relevant widespread diseases, with a prevalence of currently 55 million people with dementia worldwide. 2 key findings →

Participants: 135 Evidence: low

Full summary, score breakdown and related studies → Original source

Behavioral marker-based predictive modeling of functional status for older adults with subjective cognitive decline and mild cognitive impairment: Study protocol

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Digital health 2024-01-01

Our study will contribute to the development of self-care interventions that utilize behavioral data and machine learning techniques to provide automated analyses of the functional decline of older adults who are at risk for dementia. 1 key finding →

Participants: 130 Evidence: low

Full summary, score breakdown and related studies → Original source

Discriminative Power of Seoul Cognitive Status Test in Differentiating Subjective Cognitive Decline, Amnestic Mild Cognitive Impairment, and Dementia Based on CERAD-K Standards

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Dementia and neurocognitive disorders 2024-07-16

Differences in total score, cognitive domain scores, and subtest scores of the SCST among the 3 groups of participants diagnosed using CERAD-K confirm the clinical utility of the SCST for cognitive assessment. 4 key findings →

Participants: 296 Evidence: low

Full summary, score breakdown and related studies → Original source

Remote digital cognitive assessment in a trial-ready Alzheimer's disease cohort: A scalable approach for early intervention studies

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Alzheimer's & dementia (New York, N. Y.) 2026-07-01

High-frequency remote cognitive assessment is feasible, reliable, and valid in a relatively young international ADAD cohort. 1 key finding →

Evidence: moderate

Full summary, score breakdown and related studies → Original source

Type 2 Diabetes and Biomarkers of Brain Structure, Perfusion, Metabolism, and Function in Late Mid-Life: A Multimodal Discordant Twin Study

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of Alzheimer's disease : JAD 2024-01-01

T2D-related brain dysfunction in mid-life manifests as attentional loss accompanied by evidence of subtle neurodegeneration and global reduction in cerebral metabolism, in the absence of overt cerebrovascular disease. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source

The mini-mental state examination: a comprehensive review

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of the American Geriatrics Society 1992-09-01

The purpose of this paper is to provide a comprehensive review of information accumulated over the past 26 years regarding the psychometric properties and utility of the Mini-Mental State Examination (MMSE). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Mapping scores onto stages: mini-mental state examination and clinical dementia rating

✓ Peer-reviewed alzhub usefulness score 52 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2006-02-01

Although the clinical course of Alzheimer disease (AD) is gradual, it is useful for a number of reasons to distinguish between different levels of severity. 4 key findings →

Participants: 524 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Movement disorders : official journal of the Movement Disorder Society 2008-01-01

Dementia is an important and increasingly recognized problem in Parkinson's disease (PD). 4 key findings →

Participants: 88 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The MDS Cognition Scale: a valid instrument for identifying and staging nursing home residents with dementia using the minimum data set

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of the American Geriatrics Society 1994-11-01

We report the development and validation of an MDS-based cognitive index, the MDS Cognition Scale (MDS-COGS), by evaluating it against two popular dementia rating scales, the Global Deterioration Scale (GDS) and the Mini-Mental State Examination (MMSE). 4 key findings →

Design: cross-sectional Participants: 133 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study

✓ Peer-reviewed alzhub usefulness score 52 out of 100. The British journal of nutrition 2003-04-01

Low n-3 polyunsaturated fatty acid (PUFA) status may be associated with neuro-degenerative disorders, in particular Alzheimer's disease, which has been associated with poor dietary fish or n-3 PUFA intake, and low docosahexaenoic acid (DHA) status. 4 key findings →

Design: case-control study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias

✓ Peer-reviewed alzhub usefulness score 52 out of 100. The Journal of neuropsychiatry and clinical neurosciences 2003-01-01

The purpose of this study was to assess the cross-sectional prevalence and characteristics of anxiety among patients with Alzheimer's disease (AD), as compared with patients with frontotemporal dementia (FTD), patients with vascular dementia (VaD), and normal control subjects. 4 key findings →

Design: cross-sectional Participants: 115 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2012-06-01

The CDR-SB assesses both cognitive and functional domains of AD disability. 4 key findings →

Participants: 382 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Self-efficacy for managing dementia may protect against burden and depression in Alzheimer's caregivers

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Aging & mental health 2011-05-24

Self-efficacy is the belief that one can perform a specific task or behaviour and is a modifiable attribute which has been shown to influence health behaviours. 4 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cortical microinfarcts on 3T MRI: Clinical correlates in memory-clinic patients

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2015-05-05

This is the first study to assess cerebral microinfarcts (CMIs) on 3 tesla (3T) magnetic resonance imaging (MRI) in a memory clinic population. 4 key findings →

Participants: 238 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mini Mental State Examination and Logical Memory scores for entry into Alzheimer's disease trials

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's research & therapy 2016-02-22

Specific cutoff scores on the Mini Mental State Examination (MMSE) and the Logical Memory (LM) test are used to determine inclusion in Alzheimer's disease (AD) clinical trials and diagnostic studies. 4 key findings →

Participants: 23,438 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of neurology, neurosurgery, and psychiatry 2016-10-06

FDG-PET was performed on a cohort of 79 patients with newly diagnosed PD (mean disease duration 8 months) and 20 unrelated controls. 4 key findings →

Participants: 79 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Does loneliness mediate the relation between social support and cognitive functioning in later life?

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Social science & medicine (1982) 2013-09-15

Research in gerontology has demonstrated mixed effects of social support on cognitive decline and dementia: Social support has been shown to be protective in some studies, but not in others. 4 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events